Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Antibiotics have led to considerable increases in life expectancy. However, over time, antimicrobial resistance has accelerated and is now a significant global public health concern. Understanding societal preferences for the use of antibiotics as well as eliciting the willingness to pay for future research is crucial.
Objective: To investigate preferences for different strategies to optimize antibiotic use and to understand the willingness to pay for future research in antimicrobial resistance and antimicrobial drug development.
Methods: A discrete-choice experiment was administered to a sample of the UK general population. Respondents were asked to make nine choices, each offering three options-two hypothetical "doctor and antibiotics" and one "no doctor-no antibiotics"-defined by five attributes: treatment, days needed to recover, risk of bacterial infection that needs antibiotics, risk of common side effects, and risk of antimicrobial resistance by 2050. Data were analyzed using random parameters logit models. A double-bounded contingent valuation was also included in the survey to explore the willingness to pay for policies to contain antimicrobial resistance.
Results: Among the 2579 respondents who completed the survey, 1151 always selected "no doctor-no antibiotics" and 57 never varied their choices; therefore, 1371 responses were used in the analysis. Risk of antimicrobial resistance by 2050 was the most important attribute and the "treatment" was the least important attribute, although this was sensitive to a higher risk of bacterial infection. The aggregate annual willingness to pay for containing antimicrobial resistance was approximately £8.35 billion (~£5-£10 billion).
Conclusions: The antimicrobial resistance risk is relevant and important to the general public. The high willingness to pay suggests that large investments in policies or interventions to combat antimicrobial resistance are justified.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8403518 | PMC |
| http://dx.doi.org/10.1007/s40273-021-01076-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Antibiotic Therapy for Pyelonephritis in the Emergency Department.
Emerg Med Australas
October 2025
Emergency and Trauma Centre, The Alfred Hospital, Melbourne, Victoria, Australia.
Objectives: Acute pyelonephritis (APN) is a common diagnosis among patients presenting to the Emergency Department (ED). It is treated by empiric antibiotics within the ED. With a rise in antimicrobial resistance globally, it is unknown whether patients are being managed with empiric antibiotics that are appropriate for the causative organisms of APN.
View Article and Find Full Text PDFPharmacokinetics and Penetration of a Novel Pharmacodynamically Optimized, Carbapenem-Sparing Antibiotic, WCK 4282 (Cefepime/Tazobactam), into Epithelial Lining Fluid of Healthy, Lung-, and Thigh-Infected Neutropenic Mice.
Microb Drug Resist
September 2025
Drug Discovery Research, Wockhardt Research Centre, Wockhardt Ltd., Chhatrapati Sambhajinagar, India.
Cefepime (FEP), a fourth-generation cephalosporin combined with tazobactam (TAZ), a β-lactamase inhibitor, is being developed by Wockhardt as a pharmacodynamically optimized fixed dose combination (FEP-2 g + TAZ-2 g) for the treatment of multidrug-resistant Gram-negative infections. To undertake an exposure-response analysis for establishing pharmacokinetic (PK)/pharmacodynamic (PD) targets, it is crucial to characterize the PK profile of compounds in surrogate compartments, such as plasma and lung, in clinically relevant animal infection models used to evaluate efficacy. In the current study, PKs of FEP and TAZ were assessed in plasma and in epithelial lining fluid (ELF) of neutropenic noninfected, lung-infected, and thigh-infected mice.
View Article and Find Full Text PDFShort-Course Antibiotic Agent Therapy for Early Ventilator-Associated Pneumonia in Patients with Trauma.
Surg Infect (Larchmt)
September 2025
Department of Surgery, Division of Acute Care Surgery, University of Florida College of Medicine, Gainesville, Florida, USA.
Patients with traumatic injuries who develop ventilator-associated pneumonia (VAP) incur a higher risk of developing multi-drug resistance. Shorter duration of antibiotic agents for early VAP at five days may reduce antibiotic agent exposure without worsening patient outcomes. This retrospective cohort study performed at a Level I Trauma Center included adult (≥16 years old) patients with trauma diagnosed with bronchoalveolar lavage (BAL)-proven early (within four days of intubation) bacterial VAP.
View Article and Find Full Text PDFScreening extracts for antimicrobial compounds against methicillin-resistant and helper-compounds against aminoglycoside-resistant .
Open Res Eur
September 2025
Veterinary and Animal Sciences, University of Copenhagen, Frederiksberg, 1870, Denmark.
Background: Innovative antibiotic discovery strategies are urgently needed to successfully combat infections caused by multi-drug-resistant bacteria.
Methods: We employed a direct screening approach to identify compounds with antimicrobial and antimicrobial helper-drug activity against Gram-positive and Gram-negative bacteria. We used this platform in two different strains of methicillin-resistant (MRSA) and aminoglycoside-resistant strains of to screen for antimicrobials compounds, which potentiate the activity of aminoglycoside antibiotics.
Quality of Multidisciplinary Team Management in Healthcare-Associated Infection Prevention and Control and Its Impact on Multidrug-Resistant Organism Infections.
FASEB J
September 2025
Intensive Care Unit, Dongguan Traditional Chinese Medicine Hospital, Dongguan, Guangdong Province, China.
This study aimed to evaluate the quality of multidisciplinary team (MDT) management in healthcare-associated infection (HAI) prevention and control, as well as its impact on multidrug-resistant organism (MDRO) infections. This was a retrospective, single-center study with a small sample size. A total of 400 patients admitted to the Departments of Critical Care Medicine or Orthopedics between January 2022 and December 2023 were divided into a control group (n = 200, receiving conventional HAI management) and an experimental group (n = 200, undergoing MDT management).
View Article and Find Full Text PDF